Clinical Trial Detail

NCT ID NCT03582475
Title Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or Prostate
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Jonsson Comprehensive Cancer Center

prostate neuroendocrine neoplasm

urethra cancer

prostate small cell carcinoma

ureter small cell carcinoma

urinary bladder small cell neuroendocrine carcinoma



Carboplatin + Docetaxel + Etoposide + Pembrolizumab

Cisplatin + Etoposide + Pembrolizumab


Carboplatin + Etoposide + Pembrolizumab

Age Groups: senior adult

No variant requirements are available.